Contribute Try STAT+ Today

WASHINGTON — President Trump’s Rose Garden speech on drug prices is over. The media blitz that initially animated his top health lieutenants is fading. Now the administration has to take action.

Overwhelmingly, the bulk of the Trump administration plan to bring down drug prices — to force companies to include a medication’s price in their TV commercials or expand the way pharmacy benefit managers negotiate prices for costly cancer treatments, for example — falls under the authority of Health and Human Services Department and two of its most prominent agencies, the Food and Drug Administration and the Centers for Medicare and Medicaid Services.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.